Wednesday, May 27, 2020 Daily Archives

Protein A Chromatography: Using Automation Instead of Multiple Columns To Increase Productivity

by

This webcast features: Van Leang, Senior Director of Global CMC Operations, HJB Bio Vendors supporting biologics manufacturing are developing equipment to enable continuous process in downstream operations. Using continuous downstream operations reduces operational time and raw material costs. HJB has developed a downstream hybrid process that uses an automated batch approach to achieve a continuous downstream capture process. This allows the use of the current monoclonal antibody (MAb) capture platform but reduces cost overall by adopting the benefits of continuous…

May 27, 2020

In brief: GSK inks $231m ‘flexible’ deal with Samsung BioLogics

by

GSK says the eight-year agreement with the Korean CDMO brings additional and flexible capacity to manufacture its innovative biopharmaceutical therapies. UK-headquartered pharma giant GlaxoSmithKline (GSK) has an extensive manufacturing network to support its biologics product portfolio but has turned to contract development and manufacturing organization (CDMO) Samsung BioLogics to secure capacity for future needs. The deal will see Samsung Biologics provide GSK with additional capacity for large-scale biomanufacturing from its site in Incheon, South Korea. The capacity will be flexible…

May 27, 2020

Technology-Ready Processes for Gene Therapy Manufacturing 2.0

by

This webcast features: René Gantier, PhD, Director of Technology, Gene Therapy, Repligen The current manufacturing processes for viral vectors for gene therapy, which we can define as Gene Therapy Manufacturing 1.0 (e.g., adherent cell culture and transient expression from plasmid transfection), are not productive enough to meet the future demand considering the quickly increasing number of approved gene therapies and clinical trials. A transition is therefore ongoing to implement more productive and scalable processes, leading to Gene Therapy Manufacturing 2.0 using…

May 27, 2020

Viral vector vaccines and a nucleotide: Merck enters the COVID game

by

A triumvirate of deals, including the acquisition of a firm that uses the measles virus as a carrier for vaccines, sees Merck & Co. jumpstart its COVID-19 efforts. The first of the three announcements – which all came on the same day – will see Merck & Co. acquire vaccine developer Themis. The private Austrian firm is already working with Merck to develop vaccine candidates using its viral vector platform. The technology, developed at the Institut Pasteur and licensed to…

May 27, 2020